Monday, April 9, 2007
Like kinases, ligases are a ripe target area. The difference is that ligases
generally are harder to inhibit. Rigel Inc. thinks it achieved proof of principle
in the ubiquitin ligase field for cancer a few years back, and now has advanced
a small molecule ubiquitin ligase program in the infectious disease space.
Both protein kinases and ubiquitin ligases have similar roles: they modify
protein function. Kinases do so by adding phosphate to a given substrate, while
ubiquitin ligases work by adding ubiquitin.